EAHAD 2025 4 - 7 February 2025

Annualised bleeding rates in patients with haemophilia A or B and inhibitors with and without target joints at baseline: Results from the concizumab phase 3 explorer7 study

Authors :

Linari S1; Apte S2; Boban A3; Brown Frandsen R4; Mahlangu J5; Martins Mazini Tavares C4; Matsushita T6; Nekkal S7; Sathar J8; Chan AKC9, Shapiro A10

Affiliations
View Details Hide Details
Keywords
Rare Blood Disorders
Congress poster
Concizumab